Caladrius Biosciences, Inc. Announces Addition of Three Clinical Sites, Including University of California, San Francisco, for the Ongoing Phase 2 Study of CLBS03 in T1D
January 25, 2017 at 07:30 am EST
Share
Caladrius Biosciences, Inc. announced that three additional clinical sites, including UCSF Benioff Children’s Hospital San Francisco, under the direction of investigator Stephen Gitelman, MD, have opened to enroll subjects for the Company’s Phase 2 clinical trial of CLBS03 in type 1 diabetes, The Sanford Project: T-Rex Study. The other clinical sites include University of Florida Diabetes Institute (under Michael Haller, MD) and the Harold Schnitzer Diabetes Health Center at Oregon Health & Science University (under Ines Guttman-Bauman, MD). These sites will contribute to the continued enrollment of subjects in the trial to meet the total of 111. The study is evaluating CLBS03 (the Company’s product candidate consisting of autologous expanded regulatory T cells, or Tregs) as a treatment for recent-onset type 1 diabetes (T1D). These three clinical sites join existing clinical sites for the T-Rex Study at Sanford Research (Sioux Falls, South Dakota under Kurt Griffin, MD, PhD and Fargo, North Dakota under Luis Casas, MD), the Barbara Davis Center for Diabetes in Aurora, Colorado under Peter Gottlieb, MD and Indiana University under Linda DiMeglio, MD, MPH. The study is expected to include approximately 12 U.S. study sites.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.
Caladrius Biosciences, Inc. Announces Addition of Three Clinical Sites, Including University of California, San Francisco, for the Ongoing Phase 2 Study of CLBS03 in T1D